Shares of ChemoCentryx Inc (NASDAQ:CCXI) saw an uptick in trading volume on Thursday . 1,447,496 shares traded hands during trading, an increase of 162% from the previous session’s volume of 553,265 shares.The stock last traded at $8.63 and had previously closed at $6.19.

Several research firms have issued reports on CCXI. Zacks Investment Research raised ChemoCentryx from a “hold” rating to a “buy” rating and set a $9.00 price target for the company in a report on Tuesday, October 10th. ValuEngine lowered ChemoCentryx from a “hold” rating to a “sell” rating in a report on Friday, November 10th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $8.25.

ChemoCentryx (NASDAQ:CCXI) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. analysts expect that ChemoCentryx Inc will post -0.67 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CCXI. Bank of Montreal Can bought a new position in shares of ChemoCentryx in the second quarter worth about $102,000. Russell Investments Group Ltd. boosted its stake in shares of ChemoCentryx by 23.3% in the second quarter. Russell Investments Group Ltd. now owns 116,087 shares of the biopharmaceutical company’s stock worth $1,087,000 after acquiring an additional 21,922 shares during the period. Schwab Charles Investment Management Inc. boosted its stake in shares of ChemoCentryx by 80.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 57,800 shares of the biopharmaceutical company’s stock worth $542,000 after acquiring an additional 25,800 shares during the period. State of Wisconsin Investment Board bought a new position in shares of ChemoCentryx in the second quarter worth about $178,000. Finally, Federated Investors Inc. PA boosted its stake in shares of ChemoCentryx by 6.1% in the second quarter. Federated Investors Inc. PA now owns 111,230 shares of the biopharmaceutical company’s stock worth $1,041,000 after acquiring an additional 6,399 shares during the period. 48.89% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “ChemoCentryx (CCXI) Sees Large Volume Increase” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://www.thecerbatgem.com/2018/01/06/chemocentryx-ccxi-sees-large-volume-increase.html.

ChemoCentryx Company Profile

ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.

Receive News & Stock Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related stocks with our FREE daily email newsletter.